4,593 Shares in Jazz Pharmaceuticals PLC $JAZZ Purchased by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC bought a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 4,593 shares of the specialty pharmaceutical company’s stock, valued at approximately $605,000.

Several other large investors have also modified their holdings of JAZZ. Farther Finance Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 754.8% during the third quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after purchasing an additional 234 shares in the last quarter. Hantz Financial Services Inc. lifted its holdings in Jazz Pharmaceuticals by 471.4% during the second quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock worth $38,000 after buying an additional 297 shares during the period. Quent Capital LLC purchased a new stake in Jazz Pharmaceuticals during the third quarter worth $44,000. Geneos Wealth Management Inc. boosted its position in Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 137 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Jazz Pharmaceuticals by 30.7% in the 3rd quarter. GAMMA Investing LLC now owns 655 shares of the specialty pharmaceutical company’s stock valued at $86,000 after acquiring an additional 154 shares during the period. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $168.71 on Monday. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $182.99. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.44 and a current ratio of 1.65. The firm has a market capitalization of $10.25 billion, a price-to-earnings ratio of -27.79, a PEG ratio of 0.92 and a beta of 0.27. The stock’s 50-day simple moving average is $170.14 and its 200-day simple moving average is $142.06.

Insiders Place Their Bets

In related news, Director Heather Ann Mcsharry sold 3,415 shares of the firm’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $177.78, for a total value of $607,118.70. Following the completion of the transaction, the director owned 20,449 shares in the company, valued at $3,635,423.22. This trade represents a 14.31% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Rick E. Winningham sold 5,500 shares of the business’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $180.86, for a total value of $994,730.00. Following the sale, the director owned 8,893 shares in the company, valued at approximately $1,608,387.98. The trade was a 38.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 123,791 shares of company stock valued at $21,991,850. Corporate insiders own 4.30% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on JAZZ. Morgan Stanley restated an “overweight” rating and set a $225.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, January 8th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Monday, December 29th. JPMorgan Chase & Co. lowered their price target on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a report on Monday, October 27th. Wall Street Zen raised shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Finally, Bank of America increased their target price on shares of Jazz Pharmaceuticals from $230.00 to $247.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Thirteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $205.67.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.